Idenix Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and France. Its primary research and development focus is on the treatment of patients with hepatitis C virus (HCV). The company’s HCV discovery program focuses on various classes of drugs, including nucleoside/nucleotide polymerase inhibitors, NS5A inhibitors, protease inhibitors, and non-nucleoside polymerase inhibitors. It also develops non-nucleoside reverse transcriptase inhibitors for the treatment of human immunodeficiency (HIV) virus type-1 and acquired immune deficiency syndrome (AIDS); and products and drug candidates for the treatment of patients with hepatitis B virus (HBV). The company has a collaboration agreement with Janssen Pharmaceuticals, Inc.; ViiV Healthcare Company; Novartis; and GlaxoSmithKline. Idenix Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Key Statistics